Aims Cardiac involvement in sarcoidosis is reported in up to 30% of patients. Left ventricular involvement demonstrated by contrast-enhanced cardiac magnetic resonance has been well validated. We sought to determine the prevalence and distribution of right ventricular late gadolinium enhancement in patients diagnosed with pulmonary sarcoidosis. Methods and results We prospectively evaluated 87 patients diagnosed with pulmonary sarcoidosis with contrast-enhanced cardiac magnetic resonance for right ventricular involvement. Pulmonary artery pressures were non-invasively evaluated with Doppler echocardiography. Patient characteristics were compared between the groups with and without right ventricular involvement, and right ventricular enhancement was correlated with pulmonary hypertension, ventricular mass, volume, and systolic function. Left ventricular late gadolinium enhancement was demonstrated in 30 patients (34%). Fourteen patients (16%) had right ventricular late gadolinium enhancement, with sole right ventricular enhancement in only two patients. The pattern of right ventricular enhancement consisted of right ventricular outflow tract enhancement in 1 patient, free wall enhancement in 8 patients, ventricular insertion point enhancement in 10 patients, and enhancement of the right side of the interventricular septum in 11 patients. Pulmonary arterial hypertension correlated with the presence of right ventricular enhancement (P < 0.001). Right ventricular enhancement correlated with systolic ventricular dysfunction (P < 0.001), hypertrophy (P = 0.001), and dilation (P < 0.001). Conclusions Right ventricular enhancement was present in 16% of patients diagnosed with pulmonary sarcoidosis and in 48% of patients with left ventricular enhancement. The presence of right ventricular enhancement correlated with pulmonary arterial hypertension, right ventricular systolic dysfunction, hypertrophy, and dilation.
Introduction
Sarcoidosis is a rare, inflammatory condition, resulting from an uncontrolled cellular inflammatory response in genetically predisposed individuals, which affects the heart in approximately a third of patients. 1 Left ventricular involvement demonstrated by contrast-enhanced cardiac magnetic resonance has been well validated. 2 Until recently, limited attention has been given to right ventricular involvement in cardiac sarcoidosis, its prevalence, relevance, and prognostic value. 3 Cardiac magnetic resonance imaging is the preferred imaging tool to evaluate the healthy and diseased right ventricle. 4, 5 Right ventricular volumes, mass, and function can be quantified without geometric assumptions and excellent intra-observer and inter-observer agreement and inter-study reproducibility. [4] [5] [6] Delayed contrast-enhanced magnetic resonance allows for the detection and quantification of focal scar and interstitial fibrosis. Although there are numerous reports on delayed contrast-enhanced cardiac magnetic resonance delineating left ventricular sarcoidosis, relatively few studies have reported on right ventricular involvement. 3, [7] [8] [9] [10] We sought to determine the prevalence and distribution of right ventricular late gadolinium enhancement in patients diagnosed with pulmonary sarcoidosis and determine the relationship with pulmonary hypertension, ventricular volume, mass, and systolic function.
Methods

Patient selection
Between July 2001 and March 2014, we enrolled 87 consecutive patients with histologically proven pulmonary sarcoidosis. Cardiac evaluation was performed because of symptoms or routine screening to exclude cardiac involvement. Patients were excluded when the standard contra-indications for contrast-enhanced cardiac magnetic resonance existed. Institutional Review Board approval was obtained for this study.
Baseline investigations
Baseline investigations included 12-lead electrocardiography, Doppler echocardiography, and contrast-enhanced cardiac magnetic resonance. Pulmonary artery systolic pressure was estimated from the tricuspid regurgitant velocity plus an estimate of right atrial pressure derived from the inferior vena cava. 11 Right-sided heart studies 12 were performed in patients with pulmonary hypertension and congestive heart failure and in patients in whom automated cardioverter defibrillators were implanted. Coronary angiography was performed to exclude underlying coronary artery disease in patients with documented ventricular tachy-arrhythmias, pathological Q-waves, impaired systolic function, regional wall motion abnormalities, and/or late gadolinium enhancement.
Cardiac magnetic resonance protocol and analysis
Studies were performed using a commercial 1.5 T scanner with a cardiac-dedicated phased-array coil. The cardiac magnetic resonance studies were electrocardiographically triggered by standard software. Studies consisted of multi-phase multi-slice steady-state-free precession and fat-saturated T2-weighted (69) breath-hold sequences of the short axis, vertical long axis, and horizontal long axis views. Outflow tract views were generated in patients with right ventricular abnormalities. The short-axis images covered the left ventricle from base to apex. The steady-state-free precession sequences (typical repetition time 3.5 ms; echo time 1.4 ms; flip angle 55°; temporal resolution 50 ms; voxel size 1.6 × 1.6 × 10 mm, no gap) were performed to assess regional wall-motion abnormalities, left and right ventricular masses, volumes, and ejection fractions. Papillary muscles were included when determining right ventricular mass and excluded when determining volumes. Contrastenhanced and T2-weighted images were obtained in diastole to minimize artefact due to cardiac motion. Ten minutes after the additional administration of 0.1 mmol/kg gadolinium-diethylenetriaminepenta-acetic acid (Schering, Berlin, Germany), a two-dimensional segmented inversion recovery-gradient echo breath-hold sequence (short axis, vertical long axis, horizontal long axis, and right ventricular outflow tract in selected patients, voxel size 1.6 × 1.6 × 10 mm, without gap) was used to assess for late gadolinium enhancement. The inversion time (250 to 400 ms) was determined on an individual basis to obtain optimal nulling of the unenhanced myocardial signal. Two experienced, blinded, and independent observers used commercially available software (CAAS MRV 3.4, Pie Medical Imaging, Maastricht, the Netherlands) to determine the standard parameters delineated in Table 1 . The distribution of right ventricular late gadolinium enhancement was determined by consensus and characterized as free wall, apical, outflow tract, right-sided interventricular septal, and/or including the ventricular insertion points. Late ventricular gadolinium enhancement was considered present only if confirmed on both short-axis and matching long-axis myocardial locations. Late left ventricular gadolinium enhancement was quantified by a semiautomatic detection method using the signal intensity threshold of ≥2 SD above a remote reference region. The intra-observer and interobserver variabilities were determined by calculating the variability coefficients and intra-class correlations for each parameter in 18 randomly selected studies.
Variables and definitions
Peak systolic right ventricular pressures over 35 mmHg were considered to represent pulmonary hypertension. Right ventricular hypertrophy was defined as right ventricular weight exceeding normal values as published by Maceira et al. and/or right ventricular end-diastolic wall thickness over 5 mm. 6 Right ventricular systolic dysfunction was defined as an ejection fraction below 45%. 13 
Statistical analysis
All statistical analyses were performed using statistical software (Version 21.0, SPSS; Chicago, IL, USA). Continuous normal distributed variables were expressed as mean ± SD and, between group comparisons, were made using the parametric t-test for independent samples or the MannWhitney test when appropriate. In the non-normally distributed continuous data, the median and interquartile range were determined and, between group correlations, were made with the Wilcoxon test. Categorical variables were assessed using the χ 2 or Fisher's exact test when appropriate. Statistical significance was defined at P < 0.05. Table 1 demonstrates the baseline characteristics in the included 87 patients. Twenty-seven (31%) patients presented with cardiac symptoms, while the remaining 60 either suffered from non-specific symptoms or were routinely screened for cardiac sarcoidosis. According to the ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities, an implantable cardioverter defibrillator or pacemaker was implanted in respectively 14 and 3 patients after the baseline cardiac magnetic resonance study.
Results
Patient characteristics
14 All had late gadolinium enhancement and suffered from cardiac symptoms. When applying the recently 15 Cardiac magnetic resonance analyses Thirty patients (34%) had left ventricular and 14 patients (16%) had right ventricular enhancement, with enhancement limited to the right ventricle in only two patients (2%). The group of patients with right ventricular enhancement had significantly more extensive left ventricular enhancement compared with those without ( Table 1 , P = 0.007). Table 2 describes the distribution of right ventricular enhancement. Right ventricular enhancement correlated with early diastolic left-sided septal displacement (P = 0.002), systolic right ventricular dysfunction (P < 0.001), hypertrophy (P < 0.001), and dilation (P = 0.009). Fifteen patients had pulmonary hypertension, eight of which had right ventricular enhancement. The presence of ventricular insertion point enhancement (P = 0.007), right-sided septal (P < 0.001), and right ventricular free wall enhancement (P = 0.016) correlated with the presence of pulmonary hypertension. Right ventricular hypertrophy correlated with the presence of ventricular insertion point enhancement (P = 0.004) and right-sided septal (P = 0.001), but not with free wall enhancement (P = 0.076). In five patients, early diastolic septal displacement towards the left ventricle was observed, two of which had insertion point enhancement (P = 0.099), and three of which had right-sided septal enhancement (P = 0.013). Neither the chronicity of pulmonary sarcoidosis, as determined by the time since diagnosis, nor the extent of lung disease as determined by high-resolution computed tomography correlated with pulmonary hypertension, right ventricular systolic function, or myocardial enhancement. The right ventricular end-diastolic volume index in patients with pulmonary Stage 4 (fibro-cystic disease) was significantly larger compared with the earlier disease Stage 1 (hilar nodes only) (P = 0.027). The T2-weighted studies suggested active, granulomatous disease in only 10/69 (14%) of patients. The intra-observer variability for right ventricular end-diastolic volume was 2%, end-systolic volume 3.4%, ejection fraction 3.4%, and mass 4%. The interobserver variability for right ventricular end-diastolic volume was 1.6%, end-systolic volume 5%, ejection fraction 3.2%, and mass 8%.
Discussion
This is the first prospective cardiac magnetic resonance study to specifically report on the prevalence and distribution of right ventricular involvement in cardiac sarcoidosis. Predominant or isolated right ventricular involvement is rare, with nearly all patients suffering from left ventricular disease. 16 However, the localizations of the arrhythmogenic foci were not reported on. Because right ventricular sarcoidosis occurs in patients with more extensive left ventricular disease, the reported prognostic relevance of right ventricular disease may at least partly reflect the extent of left ventricular arrhythmogenic substrate.
Several post-transplant and post-mortem studies in sarcoidosis patients have reported right ventricular involvement to range from 6%, in patients dying from alternate causes, to as high as 65% in those dying from sudden cardiac deaths. [21] [22] [23] [24] [25] Generally, patients with congestive failure were found to have extensive biventricular sarcoid (Figure 1) , and in those who had died suddenly, active granulomatous infiltration and patchy scar were present. Right ventricular outflow tract involvement was rare (Figure 2) .
Ten recent studies employing contrast-enhanced magnetic resonance in the assessment of cardiac sarcoidosis reported on right ventricular disease in sarcoidosis (Table 3) .
3,7-10, [17] [18] [19] [20] 26 Our findings in an unselected population with pulmonary sarcoidosis compare. Right ventricular enhancement was reported in five of these studies and ranged from 2% in unselected to 48% in high-risk populations, which compares with our 47% of patients with left ventricular sarcoidosis.
3,7-10 Similar to our findings, nearly all patients with right ventricular enhancement had left ventricular enhancement. Samar et al., Patel et al., and Crawford et al. were the only researchers to report on right ventricular enhancement in more detail. 3, 7, 10 Contrary to our and other studies, Samar et al. reported that right ventricular enhancement did not correlate with a difference in left ventricular ejection fraction. His data were included in a poster presentation, which precluded detail, while relevant data were not available in 19% of patients. 3 Crawford reported multi-focal Right ventricular sarcoidosis 539 right ventricular enhancement in nearly half of those with left ventricular enhancement, basal, mid, or apical right ventricular segments being equally involved. 10 Similar to Crawford et al., the majority of our patients (70%) had multi-focal right ventricular enhancement. However, most of our patients had right-sided septal enhancement, similar to Patel's findings.
7 Right-sided septal and insertion point enhancement were related to pulmonary hypertension in eight of our patients. Crawford et al.
The presence of right ventricular enhancement correlated with hypertrophy, dilation, and systolic dysfunction. The relationship between pulmonary hypertension, right ventricular hypertrophy, dilation, systolic dysfunction, septal displacement, and septal and insertion point enhancement has been demonstrated before 12 ( Figure 3) . Right ventricular enhancement in sarcoidosis may be caused by direct granulomatous infiltration but also be related to pulmonary hypertension 12 (Figures 1 and 3) . Right ventricular hypertrophy, dilation, dysfunction, and enhancement may be secondary to pulmonary hypertension and are associated with worse prognosis.
12, 27 Pulmonary hypertension is found in 6-28% of the general sarcoidosis outpatient setting and Figure 2 Contrast-enhanced magnetic resonance study (inversionrecovery gradient echo sequence, end-diastolic frame, and short axis view) demonstrates enhancement of the right ventricular free wall (arrow), ventricular insertion points (triangles), and right-sided septum (arrow). may be secondary to pulmonary fibrosis, angiitis, and/or congestive heart failure. 27 The fact that pulmonary hypertension in our population did not correlate with disease extent as determined by computed tomography illustrates the variety in pathophysiology of this condition in sarcoidosis. 28 Right ventricular dilation, systolic impairment, and inflammation, as demonstrated with positron emission tomography, in sarcoidosis have been demonstrated to predict adverse outcome in sarcoidosis. 10, 13, [17] [18] [19] 26, 29 In patients with predominant right ventricular disease, cardiac sarcoidosis needs to be differentiated from arrhythmogenic right ventricular cardiomyopathy. Distinguishing features favouring sarcoidosis consist of an older age of onset, a non-familiar pattern, wider QRS complexes, septal involvement with atrio-ventricular conduction disease, multiple arrhythmogenic foci, particularly right ventricular apical tachycardia, concomitant left ventricular disease, and the presence of mediastinal lymphadenopathy. 30 Electro-anatomic mapping, contrastenhanced magnetic resonance, and/or positron emission tomography may guide endomyocardial biopsies needed to obtain histological confirmation of the diagnosis.
We report on ventricular insertion point enhancement, a distribution pattern not specifically mentioned in the other studies. Late enhancement of the septum and insertion points may result from delayed wash-out of gadolinium due to altered myocardial fibre strain, fibre disarray, ischaemia, and fibrosis, secondary to right ventricular pressure or volume overload, and resulting septal shift.
12,31,32 Ventricular Figure 4 Contrast-enhanced magnetic resonance study (inversionrecovery gradient echo sequence and short axis view) in a patient without pulmonary hypertension demonstrates enhancement of the ventricular insertion points (arrows), papillary muscles (asterisks), and postero-lateral left ventricular segments (triangle). Figure 5 (A) Contrast-enhanced magnetic resonance study (inversionrecovery gradient echo sequence, end-diastolic frame, and short axis view) in a patient diagnosed with a high-degree atrio-ventricular block secondary to active cardiac sarcoidosis. A dual chamber pacemaker had been inserted. Ventricular insertion point enhancement is demonstrated (triangles). Pulmonary pressures were normal (asterisk-artefact of right ventricular pace lead). (B) Contrast-enhanced magnetic imaging study (inversion-recovery gradient echo sequence, end-diastolic frame, and short axis view) in the identical patient when reassessed 7 years later demonstrates substantially more enhancement of the right-sided septum (arrow) and the insertion points (triangles). The percentage time pacing had increased from 5% to 15% of the time (asterisk-artefact produced by right ventricular pace lead).
Right ventricular sarcoidosis 541 insertion point enhancement has been reported in hypertrophic cardiomyopathy, atrial septal defects, severe pulmonary hypertension, tetralogy of Fallot, transposition of the great arteries, and even a proportion of veteran healthy endurance athletes [31] [32] [33] [34] [35] (Figures 2-5 ). The amount of insertion point enhancement correlates with mean pulmonary arterial pressures, right ventricular mass, volume, and ejection fraction.
12
Pulmonary hypertension in sarcoidosis is associated with adverse outcome, particularly when accompanied by right ventricular dysfunction, and/or lung fibrosis.
12, 27 Recently, Swift et al. reported septal extension of insertion point enhancement in pulmonary hypertension to mark more severe disease, with associated right ventricular dilation, but found it not to be an independent predictor of overall mortality.
Late gadolinium enhancement includes active, potentially reversible, granulomatous inflammation, and chronic focal scar. 8, 20, 36 Immune suppressive treatment, currently a work in progress, may potentially improve systolic function and decrease arrhythmogenic substrate. 10, 20, 36 The T2-weighted spin echo-based assessment used in our study to evaluate for active granulomatous infiltration and associated oedema is rather insensitive.
8 T2 mapping and positron emission tomography have shown promise and will be included in future projects.
28,37
Conclusions
Approximately 30% of an unselected patient population with pulmonary sarcoidosis had left ventricular involvement, half of which had right ventricular involvement. More extensive left ventricular enhancement correlated with right ventricular involvement. Right ventricular enhancement may result from direct infiltration and resulting scar or pulmonary hypertension. Previous studies associated impaired systolic right ventricular function and right ventricular enhancement with ventricular tachy-arrhythmias. We demonstrate right ventricular enhancement with cardiac magnetic resonance to be mostly multi-focal, involve the septum, and correlate with increased right ventricular volumes, hypertrophy, and impaired systolic function.
Limitations
Pulmonary pressures were routinely determined noninvasively in the majority of our patients, and we may have underestimated the pulmonary pressures. Our imaging protocol was not primarily adapted to evaluate the right ventricle, our slice thickness, and potentially suboptimal myocardial nulling may have resulted in an underestimation of the presence and extent of right ventricular infiltration and scarring. Because T2 mapping was not performed, we likely underestimated active granulomatous inflammation. The relatively small number of patients included limits our findings and conclusions.
Future focus of development
Customized hybrid approaches including electrocardiography, ultrasound, positron emission tomography, and contrastenhanced magnetic resonance will provide us with more sensitive, accurate, and comprehensive information on haemodynamic, electrical, mechanical, and inflammatory characteristics of the atriae and ventricles.
